Tumor 004 (melanoma) - Keytruda (anti-PD1) resistant

Tumor 004

Internal characterization

Characterization data includes

We have characterized additional genomic and cell surface makers and work with clients in determining the expression of their drug target. Please contact us to learn more.

Assays conducted to date

  • Comparative studies using Keytruda (anti-PD-1) and Tecentriq (anti-PD-L1) candidates to measure tumor lysis)
  • Comparative studies using Yervoy (anti-CTLA4)
  • Effect of drug candidate(s) on CTL 007 migration in 3D co-culture with WC 007
  • Immunosuppressive studies using allogeneic Tregs and Macrophages on CTL 007 inhibition of WC 007 lysis

Relevant Publications

  1. X

WM 3451 (melanoma)

WM 3451

Internal characterization

Characterization data includes

We have characterized additional genomic and cell surface makers and work with clients in determining the expression of their drug target. Please contact us to learn more.

Assays conducted to date

  • Comparative studies using Keytruda (anti-PD-1) and Tecentriq (anti-PD-L1) candidates to measure tumor lysis)
  • Comparative studies using Yervoy (anti-CTLA4)
  • Effect of drug candidate(s) on CTL 007 migration in 3D co-culture with WC 007
  • Immunosuppressive studies using allogeneic Tregs and Macrophages on CTL 007 inhibition of WC 007 lysis

Relevant Publications

  1. X

WM 35 (melanoma)

WM 35,,,

Internal characterization

Characterization data includes

We have characterized additional genomic and cell surface makers and work with clients in determining the expression of their drug target. Please contact us to learn more.

Assays conducted to date

  • Comparative studies using Keytruda (anti-PD-1) and Tecentriq (anti-PD-L1) candidates to measure tumor lysis)
  • Comparative studies using Yervoy (anti-CTLA4)
  • Effect of drug candidate(s) on CTL 007 migration in 3D co-culture with WC 007
  • Immunosuppressive studies using allogeneic Tregs and Macrophages on CTL 007 inhibition of WC 007 lysis

Relevant Publications

  1. X

Solid Tumors

  • A549 (lung cancer)
  • MDA-MB-231 ATCC HTB-26
  • SK-OV-3, ATCC HTB-77
  • PANC-1, ATCC CRL-1469

For additional information and data related to these cell lines, please contact us to learn more

null

HIGHER SPECIFICITY

Higher specificity results in exquisite sensitivity between the TILs and tumors, resulting in an increased ability to detect the impact factors within the tumor microenvironment that could be masked by allogeneic responses.

null

WELL CHARACTERIZED

Highly characterized tumors (e.g. Braf mutations and STR profiles are known). Huge panel from which one can assess the impact of potential drugs.
null

ESTABLISHED DATA WITH APPROVED IMMUNE MODULATORS

Established data with anti-PD1 and anti-PD-L1 drug candidates – good for comparative studies.
null

REPEAT STUDIES ACROSS ASSAY FORMATS

A standardized and reproducible system which with one can assess immune responses across various platforms.

null

BROAD SPECTRUM APPLICATIONS IN CANCER

Apply readouts into other tumor types or indications

This is a PD-L1 sensitive tumor line

TIM-3, PD-1, CD25, CD80, HVEM, GITR, CD73, PD-L2, OX-40L, CD155, CD112, CD44, CD49a (α1 integrin), CD49b (α2 integrin), CD29 (β1 integrin), CD95 (FAS) CD54 (ICAM-1), CD11a (LFA-1a)

CTL and Tumor 001 was derived from a colon cancer patient. This HLA-matched pairing is PD-L1 sensitive.

Tumor 001

PD-L1, HVEM, OX-40L, CD155, CD112, CD44,
CD49b(α2 integrin), CD29(β1 integrin), CD95 (FAS)

Chemokines and Chemokine Receptors

CCR2,CCR3, CCL15,CCL2,CCL3,CCL4,CXCL11, CCL19,CCL21, CCL25, and CXCL9

Example studies:

  • Cytotoxity (CTL) studies
  • Immunosuppression assays to evaluate the role of Tregs and Tumro Associated Macrophages (TAMs) on CTL proliferation and apoptosis of matched tumor
  • Blocking and binding studies of known cell surface targets

 

This is a PD-1 sensitive tumor line

CTL and Tumor 002 derived from a female colon cancer patient at time of surgery. This HLA-matched cell pairing is PD-1 sensitive.

PD-1, TIGIT, OX-40, 4-1BB, CD80, CD44, CD95 CD29(β1 integrin), CD3, TCR α/β, CD95 (FAS), CD54 (ICAM-1), CD11a (LFA-1a)

Tumor 002

PD-L1, HVEM, OX-40L, CD155, CD112, CD44 CD49a (α1 integrin), CD49b (α2 integrin), CD29 (β1 integrin), CD95 (FAS)

Chemokines and Chemokine Receptors

CCR2,CCR3, CCL15,CCL2,CCL3,CCL4,CXCL11, CCL19,CCL21, CCL25, and CXCL9

Example studies:

  • Cytotoxity (CTL) studies
  • Immunosuppression assays to evaluate the role of Tregs and Tumro Associated Macrophages (TAMs) on CTL proliferation and apoptosis of matched tumor
  • Chemokine blocking studies of SDF1α and CXCR4
  • Blocking and binding studies of known cell surface targets

 

This is a PD-1 sensitive tumor line

CTL and Tumor 003 derived from a melanoma male Caucasian patient. This HLA-matched cell pairing is PD-1 and PD-L1 sensitive.

TIM-3, PD-1, 4-1BB, ICOS, CD8, CD25, CD44
CD95 (FAS),CD80(B7-1), CD29(β1 integrin), CD49b (α2 integrin), CD54 (ICAM-1), CD11a (LFA-1A)

Tumor 003

PD-L1, CD44, ICOSL, 4-1BBL, PD-L2, CD112, HVEM, CD49a (α1 integrin), CD49b (α2 integrin), CD29 (β1 integrin), CD95 (FAS)

Chemokines and Chemokine Receptors

CCR7,CCR9, CXCR3,CXCR1, CCL21,CCL25, CXCL12,CXCL19 and CXCL9

Example studies:

  • Cytotoxity (CTL) studies
  • Immunosuppression assays to evaluate the role of Tumro Associated Macrophages (TAMs) on CTL proliferation and apoptosis of matched tumor
  • Chemokine blocking studies of SDF1α and CXCR4 and affects on CTL migration
  • Blocking and binding studies of known cell surface targets